Patients at extremes of body weight are underrepresented in randomized controlled trials of
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …

Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …

Background: Limited real-world data exist on the comparative effectiveness and safety of
direct oral anticoagulants (DOACs) compared to warfarin in obese patients with atrial …

Yes. Treatment of venous thromboembolism (VTE) or atrial fibrillation in patients with
elevated BMIs with a direct oral anticoagulant (DOAC) appears to be equivalent to warfarin …

Abstract Background The 2021 International Society on Thrombosis and
Haemostasis'(ISTH) recommends standard doses of apixaban and rivaroxaban regardless …

Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …

Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a
decreased risk of bleeding when compared to warfarin for the treatment of venous …

Obese patients are frequently initiated on anticoagulation therapy for treatment or prevention
of venous thromboembolism, prevention of stroke, and systemic embolism in atrial …

Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …

DOACs are the anticoagulation drugs of choice. Using nitroglycerincontaining preparations
or sublingual glyceryl trinitrate is not permitted in morbidly obese patients. The lack of …